Section

Why Wall Street Is Chasing Ozempic Wannabes

By wsj - 5 months ago
Big Pharma can’t seem to get investors hyped on much beyond obesity, so many are jumping in. Most won’t win.

Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.